Marcadores moleculares en el cáncer de mama. Implicaciones terapéuticas

  1. Cebey López, V. 1
  2. Álvarez Fernández, J. 1
  3. Palacios Ozores, P. 1
  4. Cortegoso Mosquera, A. 1
  5. López López, R. 1
  1. 1 Servicio de Oncología Médica y Grupo de Oncología Médica Traslacional, Hospital Clínico Universitario e Instituto de Investigación Sanitaria-CIBERONC, Santiago de Compostela, La Coruña, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Título do exemplar: Enfermedades oncológicas (IV)Melanoma, cáncer de mama y tumores ginecológicos

Serie: 13

Número: 27

Páxinas: 1543-1545

Tipo: Artigo

DOI: 10.1016/J.MED.2021.03.006 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Breast cancer is one of the tumor types in which the use of biomarkers has been earlier incorporated into clinical practice and in the greatest number. Biomarkers are classified into two groups: prognostic markers and predictive response markers, but some of them belong to both groups. Biomarkers, including immunohistochemistry markers (like estrogen, progesterone receptors, HER2 and Ki67) and current ones based mainly on gene (BRCA, PI3K) and immune system (PD-L1, TILS) expression, are essential in disease classification and treatment choice. Nowadays, molecular and liquid-biopsy platforms, are being validated.

Referencias bibliográficas

  • Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144:545-63
  • Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bart-lett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142:1364-82.
  • Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
  • Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
  • Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early stage invasive breast cancer: ASCO Clinical Practice Guideline Update Integration of Results From TAILORx. J Clin Oncol. 2019;37(22):1956-64.
  • Network NCC: Breast Cancer. Version 6.2020
  • Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Brit J Cancer. 2018;119:141-52.
  • González‐Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno oncology biomarkers in breast cancer clinical trials and daily practice. J Pathology. 2020;250:667-84.
  • André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA mutated, hormone receptor positive advanced breast cancer. New Engl J Med.2019;380:1929-40.
  • Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206-23
Fonte de datos: Dialnet